- Home
- ZCMD vs VBIO Comparison
ZCMD vs VBIO Comparison
Compare ZCMD & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZCMD | VBIO |
|---|---|---|
| Founded | 2012 | N/A |
| Country | China | United States |
| Employees | N/A | 52 |
| Industry | Other Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 1.6M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZCMD | VBIO |
|---|---|---|
| Price | $1.10 | $0.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.7M | 768.1K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.25 |
| 52 Week High | $11.96 | $0.61 |
Technical Indicators
Market Signals| Indicator | ZCMD | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 32.74 |
| Support Level | $0.75 | $0.25 |
| Resistance Level | $2.70 | $0.43 |
| Average True Range (ATR) | 1.14 | 0.07 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 0.73 | 10.44 |
Price Performance
Historical ComparisonAbout ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.